Latest News

HBX Group International (BME:HBX) has just released its FY 2025 financial results, revealing second-half revenue of €401 million and net income of €158 million, with basic EPS coming in at €0.64. The company has seen revenue move from €291 million in FY 2024 H1 to €319 million in FY 2025 H1, and then up again to €401 million in FY 2025 H2. Margins moved sharply through the year, highlighting volatile profitability as HBX continues to balance growth expectations with its bottom line...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Preformed Line Products fair value estimate is US$186...

As the Australian market navigates the mixed signals from a higher-than-expected CPI reading and fluctuating sector performances, investors are closely monitoring how these dynamics impact dividend stocks. In such an environment, a good dividend stock is often characterized by its ability to maintain stable payouts and resilience amidst economic uncertainties, making them a focal point for those seeking consistent income in volatile times.

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Clal Insurance Enterprises Holdings (TASE:CLIS) just released its Q3 2025 results, posting a total revenue of ₪4.5 billion and net income of ₪592 million, with basic EPS coming in at ₪7.41. Looking at earlier quarters, revenue has ranged from ₪3.5 billion to ₪8.0 billion over recent periods, while EPS has shifted from ₪1.62 up to ₪7.68, reflecting how earnings have fluctuated from quarter to quarter. Margins have been under the spotlight, as investors watch for signs of stabilization or...

Doro (OM:DORO) has posted its third-quarter 2025 results, revealing revenue of 247.7 million SEK and basic EPS of 0.90 SEK, with net income at 21.9 million SEK. Over the past several quarters, the company has seen revenue climb from 206.7 million SEK in Q2 2024 to 247.7 million SEK in the latest quarter. EPS moved from 0.58 SEK to 0.90 SEK. Margins have remained solid, marking a stretch of steady profitability that investors will be parsing for what comes next. See our full analysis for...

One thing we could say about the analysts on Pacific Edge Limited ( NZSE:PEB ) - they aren't optimistic, having just...

Despite a 36% gain in Pacific Biosciences of California, Inc.'s ( NASDAQ:PACB ) stock price this week, shareholders...

BJ's Restaurants, Inc. ( NASDAQ:BJRI ), is not the largest company out there, but it saw a significant share price rise...

As the U.S. stock market enjoys a promising streak with major indexes on track for their best week since June, investors are eyeing opportunities across various sectors. Penny stocks, though often seen as a niche area of investment, continue to capture attention due to their potential for growth in smaller or newer companies. While the term may seem outdated, these stocks can still offer intriguing prospects when backed by solid financials and strategic positioning in the current market...

As U.S. markets experience a notable upswing, with major indexes on track for their best week since June, investors are keenly observing opportunities to bolster their portfolios amid the positive momentum. In such a dynamic environment, dividend stocks can offer stability and income potential, making them an attractive option for those looking to enhance their investment strategies in a thriving market landscape.

Key Insights The projected fair value for Topicus.com is CA$229 based on 2 Stage Free Cash Flow to Equity Topicus.com's...

Wondering if Rumble’s stock price is a hidden bargain or a red flag? Let’s break it down together with a focus on what really drives value. After a sharp jump of 24.3% over the past week, Rumble shares still show a year-to-date drop of 45.5%, making it one of the more volatile names in the media space. The buzz around Rumble is largely due to its ongoing positioning as a “free speech” video platform, its continued attempts to attract high-profile creators, and recent headlines about...

Kura Oncology recently attracted attention after KOMZIFTI, its once-daily oral menin inhibitor, secured full FDA approval for adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. This milestone addresses a treatment gap in AML care. See our latest analysis for Kura Oncology. Kura Oncology’s momentum has picked up meaningfully after KOMZIFTI’s approval, with the share price up over 48% in the past three months and 38% year-to-date. While recent investor...

Even though Intuit Inc.'s ( NASDAQ:INTU ) recent earnings release was robust, the market didn't seem to notice. Our...

It's not a stretch to say that IMCD N.V.'s ( AMS:IMCD ) price-to-earnings (or "P/E") ratio of 17.6x right now seems...

International Flavors & Fragrances Inc. ( NYSE:IFF ) has announced that it will pay a dividend of $0.40 per share on...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Key Insights Trellidor Holdings to hold its Annual General Meeting on 4th of December Total pay for CEO Terry Dennison...

Yamada Holdings recently held a Board Meeting on November 17, 2025 to discuss the disposal of its own shares as part of an employee shareholding association restricted share incentive plan. This move highlights the company's focus on aligning employee interests with long-term corporate performance by expanding equity-based compensation initiatives. We'll explore how the decision to allocate shares for employee incentives may shape Yamada Holdings' overall investment narrative moving...

Frontline plc ( NYSE:FRO ) is reducing its dividend from last year's comparable payment to $0.19 on the 19th of...

It's not a stretch to say that Vivara Participações S.A.'s ( BVMF:VIVA3 ) price-to-earnings (or "P/E") ratio of 11.2x...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...

Alibaba Health Information Technology (SEHK:241) reported H1 2026 revenue of 16.3 billion CNY and basic EPS of 0.041 CNY, with net income excluding extra items at 663 million CNY. Over recent periods, revenue moved from 14.1 billion CNY in H2 2024 to 14.3 billion CNY in H1 2025, then rose to 16.3 billion CNY in H2 2025. EPS was 0.030 CNY in H2 2024, moved to 0.048 CNY in H1 2025, and landed at 0.041 CNY in H2 2025. Margins showed solid progress through these periods, helping to set the tone...